SAN DIEGO--(BUSINESS WIRE)--Assay Depot, the pharmaceutical industry’s leading marketplace for scientific services, today announced the addition of two industry experts to its board of directors. The appointments come at a pivotal time as the company positions itself to support the growing needs of an industry undergoing radical change.
“By simplifying access to research tools and experts, and sharing pre-competitive information across multiple pharmaceutical companies, Assay Depot is changing how drug research is done,” said Peter G. Schultz, the Scripps Family Chair Professor of Chemistry at The Scripps Research Institute. “I look forward to helping expand this new platform across the industry.”
Often referred to as the “Amazon.com for Scientists,” Assay Depot has developed the first and only cloud-based drug research platform that allows researchers to locate research services from qualified vendors quickly, efficiently and at no cost. Assay Depot’s network of online Research Exchanges streamline communications between scientists and 8,000+ global research vendors and – for the first time – makes it possible to develop a drug in an entirely virtual fashion using only research providers found through the site.
“Pharmaceutical innovation needs Assay Depot. It empowers scientists to explore intriguing ideas like never before,” said Bernard Munos, founder of InnoThink. “Whether they work in large or small organizations, or even alone, scientists can use Assay Depot to access the tools they need to turn their great ideas into advances that will speed the development of new therapies. It’s a game-changer.”
- Peter G. Schultz, PhD is a world-renowned chemist-entrepreneur. He is a member of the U.S. National Academy of Sciences and the Institute of Medicine. He founded the Genomics Institute of the Novartis Research Foundation (GNF) in 1999 and the non-profit California Institute for Biomedical Research (CALIBR) in 2012. Peter has more than 500 scientific publications and he has founded nine drug discovery and technology companies, including Affymax, Syrrx, Symyx, Phenomix, Ilypsa, Kalypsys, Ardelyx, Wildcat Technologies and Ambrx. His awards include the Waterman Award of the National Science Foundation, the 1994 Wolf Prize in Chemistry, the 2003 Paul Ehrlich Prize, and the 2005 Arthur C. Cope Award of the American Chemical Society.
- Bernard H. Munos, PhD is the founder of InnoThink, a consultancy that focuses on pharmaceutical innovation. He previously served as an Advisor for corporate strategy at Eli Lilly, where he focused on disruptive innovation and the radical redesign of R&D. His research has been published in Nature and Science, and profiled by Forbes magazine. The popular industry newsletter FiercePharma has named him one of the 25 most influential people in biopharma. He is a Senior Fellow at FasterCures (a center of the Milken Institute), a member of the Advisory Council and the Cures Acceleration Network of NIH’s National Center for Advancing Translational Sciences (NCATS) and a member of the Institute of Medicine’s Forum on Drug Discovery, Development, and Translation.
“We are honored to welcome Pete Schultz and Bernard Munos to our board,” said Kevin Lustig, CEO, Assay Depot. “Their wealth of pharmaceutical experience will be invaluable as Assay Depot continues to help the industry promote innovation, reduce costs and create a more sustainable business model.”
About Assay Depot
Assay Depot is the world’s largest scientific services marketplace. The company operates a network of online Research Exchanges that dramatically streamline purchases between scientists and more than 8,000 global research vendors. Assay Depot is changing the way life science research is done. To learn more about Assay Depot’s enterprise software, visit http://enterprise.assaydepot.com. To use Assay Depot’s free public marketplace, visit http://www.assaydepot.com.
